Immunogenicity testing is one of the critical parameters for the development of biotherapeutics. Stringent recommendations pertaining to both development and subsequent validation of the ADA assays puts forth requirements for more robust and well-defined methods. The MSD assays extends support for every stage immunogenicity testing along with the following –
- Exceptional precision both for intra and inter assay range
- Superior sensitivity for determining both high and low affinities for ADA assays
- High level of drug tolerance responsible for minimizing the interference of the ADA complexes
- Minimum interference produced by matrix
- Wide ranges for reducing the further counts of sample dilutions
MSD immunogenicity assays have enabled the global scientists in preparing accurate and precise determination levels of cytokines, biomarkers, and other phosphoproteins. MSD platform is based on the electrochemiluminescence thereby providing excellent sensitivity across a large dynamic range and flexibility. Anti-drug antibody detection through the use of a simple protocol involving a homogenous solution is the base of MSD bridging format. The plus point of such MSD ELISA assays is that there is no requirement of species-specific reagents. Thus, the entire reaction is independent of both species and their isotypes thereby allowing the scientists to employ the same assay formats across both pre-clinical and clinical stages.
In toxicity studies, disease-induced changes or the compounds typically undergoes evaluation through the mediation of a combination of the histochemical endpoints along with a number of potential biomarkers. Each of these single components exhibits the potency of altering the functioning of the tissues or organs by inducing toxic changes in them. Toxicologists therefore are in constant search of assay system demonstrating consistent performance, large dynamic range, and relatively higher sensitivity. MSD technology helps the scientists in availing all these characteristics plus multiplexing to save on both the sample usage and time.
One of the key advantages that MSD platform has over ELISA is that here you can analyse several different samples within a single well at one go. While performing sandwiched Meso Scale Discovery assay, captured antibody attaches to the bottom most part of your well. Here at the bottom most part of your MSD well, you have an electrode in place of plastic. Also, the secondary antibody should be conjugated with ruthenium metal ion. The moment your secondary antibody binds to the antigen, it triggers the initiation of an oxidation-reduction reaction which ultimately radiates a beam of light which is subsequently detected by a CCD camera.
Meso Scale Discovery or MSD assay is thus a bioanalysis platform involving the core strength of chemiluminescence unlike other chemiluminescent reactions or colorimetric reactions taking place as is the case with ELISA. MSD ECL assay techniques promises following key benefits to their users –
Absolute ability to quantitate demonstrating a short processing time with a limited sample requirement.
Exhibits high levels of sensitivity with a better dynamic range thereby reducing signal-to-noise ratio. There are many MSD platform manufacturers in town offering ready-made single analyte and multiplexing kits. Such kits are popular for their lot-to-lot performance consistency and excellent performance ability.
